As the former head of cell and gene therapy at Novartis Oncology in Europe and the person responsible for launching the first-ever commercial CAR-T, it’s probably not an overreach to say that Emanuele Ostuni, PhD, has extensive knowledge about cancer treatment. He also has an insatiable appetite for challenging himself to find novel solutions for complex problems. Ostuni departed Novartis in early 2022 to take the helm of the covert start-up ARTBIO after developing a keen interest in the burgeoning field of radioligand therapy (RLT).

It was a bold move, considering how packed and fast-paced the RLT industry was already, despite its infancy. Not only were next-gen companies like RayzeBio emerging when Ostuni joined ARTBIO, but major pharmaceutical companies like Bayer had already acquired

See Full Page